Mankind Pharma Ltd.
Price
Daily candles · BSEThis range is drawn from BSE prices — our NSE daily history does not yet cover it. The price, change and 52-week range above are NSE. Shorter ranges may already be available on NSE.
What the numbers say
- Good return on equity: 3-year ROE 17.6%.
- Comfortable leverage: debt-to-equity of 0.37.
- Sales compounded at 17.7% over 3 years.
- Profits convert to cash well (CFO/OP 0.74).
- Trades above its industry P/E (49.1 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Mankind Pharma inks definitive pact to acquire majority stake in Armed Cell Therapeutics
Said investment is part of the company’s long term strategy to build a global innovation-led pharmaceutical business
- Mankind Pharma sells 100% stake in Broadway Hospitality Services
Broadway has ceased to be a wholly owned subsidiary of the company with effect from August 31, 2026
- Mankind Pharma inks pact with China’s Chongqing Chenan Biopharmaceutical
The latest partnership further reinforces the company’s commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India
- Mankind Pharma incorporates wholly owned subsidiary in Netherlands
The company has incorporated WOS under the name and style of ‘Mankind Pharma (Netherlands) B.V.’
- Mankind Pharma reports 30% rise in Q1 consolidated net profit
Consolidated total income of the company increased by 11.65% to Rs 4,075.59 crore in Q1FY27.
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 14,278 | 12,207 | 10,260 | 8,749 | 7,782 |
| Other income | 359 | 537 | 280 | 129 | 196 |
| Total Income | 14,636 | 12,744 | 10,541 | 8,878 | 7,978 |
| Expenditure | 10,655 | 9,187 | 7,745 | 6,848 | 5,791 |
| Operating Profit | 3,981 | 3,557 | 2,795 | 2,030 | 2,187 |
| Interest | 644 | 432 | 34 | 46 | 60 |
| Depreciation | 886 | 621 | 378 | 326 | 167 |
| Profit before tax | 2,333 | 2,516 | 2,398 | 1,671 | 1,975 |
| Tax | 395 | 510 | 457 | 362 | 522 |
| Net Profit | 1,938 | 2,007 | 1,941 | 1,310 | 1,453 |
| EPS (₹) | 46.35 | 49.28 | 47.75 | 32.00 | 35.78 |
| Net margin % | 13.6 | 16.4 | 18.9 | 15.0 | 18.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 41 | 41 | 40 | 40 | 40 |
| Reserves | 16,211 | 14,247 | 9,300 | 7,395 | 6,115 |
| Net worth | 16,253 | 14,289 | 9,340 | 7,435 | 6,155 |
| Total sources | 19,732 | 20,283 | 9,754 | 7,775 | 6,469 |
| Net block | 18,620 | 19,004 | 4,540 | 4,245 | 3,583 |
| Capital work in progress | 1,128 | 826 | 282 | 550 | 701 |
| Investments | 2,590 | 2,524 | 2,746 | 1,632 | 1,286 |
| Inventory | 2,144 | 2,094 | 1,553 | 1,498 | 1,760 |
| Debtors | 1,730 | 1,538 | 848 | 576 | 388 |
| Cash & bank | 483 | 555 | 708 | 453 | 406 |
| Book value (₹) | 393.72 | 346.31 | 233.15 | 185.61 | 153.65 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 3,121 | 2,413 | 2,152 | 1,813 | 920 |
| From investing | -196 | -12,683 | -2,082 | -1,054 | -1,369 |
| From financing | -2,953 | 10,233 | 5 | -740 | 605 |
| Net change in cash | -28 | -37 | 76 | 19 | 155 |
| Free cash flow | 2,925 | -10,270 | 71 | 759 | -449 |
| Closing cash | 392 | 404 | 382 | 305 | 283 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 13.2 | 18.3 | 28.4 | 23.5 | 34.0 |
| ROE % | 12.7 | 17.0 | 23.1 | 19.3 | 26.7 |
| PAT margin % | 13.0 | 15.8 | 18.2 | 14.4 | 18.0 |
| EBIT margin % | 19.9 | 23.3 | 22.8 | 18.9 | 25.2 |
| Debt / equity | 0.37 | 0.58 | 0.02 | 0.02 | 0.14 |
| Current ratio | 1.07 | 1.23 | 3.10 | 2.32 | 1.68 |
| Interest cover | 4.62 | 6.83 | 71.03 | 37.52 | 34.02 |
| Sales growth % | 17.0 | 19.0 | 17.3 | 12.4 | 25.2 |
| Dividend per share (₹) | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payout % | 2.2 | 0.0 | 0.0 | 0.0 | 0.0 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Mankind Pharma Ltd. (MANKIND) last traded at ₹2,275.60 on the NSE, down +0.43% on the session. Prices on this page are indicative and for information only.
Mankind Pharma Ltd. has traded between ₹1,909.70 and ₹2,642.00 over the last 52 weeks on the NSE.
Mankind Pharma Ltd. has a market capitalisation of about ₹93,937 crore.
Mankind Pharma Ltd. trades at a P/E of 49.1, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for MANKIND from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Mankind Pharma Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in